Traders Sell Shares of Sage Therapeutics, Inc. (SAGE) on Strength (SAGE)

Traders sold shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) on strength during trading on Friday. $10.80 million flowed into the stock on the tick-up and $30.59 million flowed out of the stock on the tick-down, for a money net flow of $19.79 million out of the stock. Of all equities tracked, Sage Therapeutics had the 15th highest net out-flow for the day. Sage Therapeutics traded up $2.27 for the day and closed at $97.71

SAGE has been the subject of a number of recent analyst reports. BMO Capital Markets reaffirmed a “buy” rating and set a $82.00 target price on shares of Sage Therapeutics in a report on Friday, July 28th. BidaskClub lowered Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. HC Wainwright lifted their target price on Sage Therapeutics to $86.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Needham & Company LLC set a $95.00 target price on Sage Therapeutics and gave the company a “buy” rating in a report on Friday, August 4th. Finally, Cowen Inc reaffirmed a “buy” rating and set a $100.00 target price on shares of Sage Therapeutics in a report on Friday, August 4th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $105.71.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.01. The firm’s revenue was up .0% compared to the same quarter last year. equities research analysts forecast that Sage Therapeutics, Inc. will post -7.38 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of SAGE. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Sage Therapeutics by 11.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 138 shares during the last quarter. Hershey Trust Co. bought a new stake in shares of Sage Therapeutics during the 3rd quarter valued at about $118,000. Oppenheimer Asset Management Inc. boosted its position in shares of Sage Therapeutics by 412.9% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 1,565 shares during the last quarter. Bessemer Group Inc. bought a new stake in shares of Sage Therapeutics during the 3rd quarter valued at about $141,000. Finally, Turner Investments LLC bought a new stake in shares of Sage Therapeutics during the 2nd quarter valued at about $159,000.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3054429/traders-sell-shares-of-sage-therapeutics-inc-sage-on-strength-sage.html.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.